We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

72 hedge funds and large institutions have $17.9M invested in Citius Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.68% → 0.68% (-0%)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

1% less funds holding

Funds holding: 73 → 72 (-1)

11% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 18

26% less capital invested

Capital invested by funds: $24.2M → $17.9M (-$6.35M)

Holders
72
Holders Change
-1
Holders Change %
-1.37%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
16
Reduced
18
Closed
20
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
+$14K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.28M
2
Millennium Management
Millennium Management
New York
+$1.47M
3
Goldman Sachs
Goldman Sachs
New York
+$788K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$451K
5
YIH
Y-Intercept (HK)
Hong Kong
+$279K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.96M
2
State Street
State Street
Massachusetts
-$1.17M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$931K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$486K
5
N
Nuveen
North Carolina
-$435K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
51
Bank of New York Mellon
New York
$8.54K -$219K -12,229 -95%
Franklin Resources
52
Franklin Resources
California
$8.33K – – –
FC
53
Fairscale Capital
New Hampshire
$7.78K +$6.56K +366 New
EFG
54
Ethos Financial Group
Pennsylvania
$6K – – –
Simplex Trading
55
Simplex Trading
Illinois
$6K +$2.46K +137 +47%
MWPCG
56
Measured Wealth Private Client Group
New Hampshire
$5.84K – – –
Morgan Stanley
57
Morgan Stanley
New York
$5.69K -$130K -7,277 -95%
Macquarie Group
58
Macquarie Group
Australia
$4.02K +$4.93K +275 New
Russell Investments Group
59
Russell Investments Group
United Kingdom
$3.19K +$3.92K +219 New
BTI
60
Blue Trust Inc
Georgia
$2.69K – – –
Wells Fargo
61
Wells Fargo
California
$2.33K -$33.6K -1,874 -92%
PGAM
62
Princeton Global Asset Management
New Jersey
$2.33K – – –
Fidelity Investments
63
Fidelity Investments
Massachusetts
$2.05K -$10.2K -571 -80%
JP Morgan Chase
64
JP Morgan Chase
New York
$1.77K -$34.5K -1,927 -94%
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$1.74K -$47.8K -2,666 -96%
QC
66
Quent Capital
New York
$1.61K – – –
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$662 -$55.1K -3,075 -99%
APC
68
Aspire Private Capital
North Carolina
$175 – – –
WWP
69
WR Wealth Planners
Missouri
$58 – – –
FFA
70
Farther Finance Advisors
California
$43 – – –
EWA
71
EverSource Wealth Advisors
Alabama
$14 – – –
N
72
Nuveen
North Carolina
– -$435K -19,386 Closed
Deutsche Bank
73
Deutsche Bank
Germany
– -$77.8K -3,457 Closed
XT
74
XTX Topco
Cayman Islands
– -$69.6K -3,104 Closed
AIG
75
American International Group
New York
– -$59.5K -2,652 Closed
1 2
3
4

CTXR Hedge Fund Activity: Q2 2024 in Review

72 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2024, worth a combined $17.9M — down 26% from $24.2M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CTXR and 19 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 16 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $7.28M. The largest seller was BlackRock, cutting an estimated $4.96M.

  • 72 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2024, down from 73 in Q1 2024.
  • Funds reported $17.9M of Citius Pharmaceuticals stock for Q2 2024, down 26% quarter-over-quarter.
  • 19 funds opened new Citius Pharmaceuticals positions in Q2 2024 and 20 closed out, a net change of -1 holder.
  • The largest Citius Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $7.28M added.
  • The largest Citius Pharmaceuticals seller in Q2 2024 was BlackRock, an estimated $4.96M sold.

Based on aggregated 13F filings for Q2 2024.